Austin A. Robinson
| Austin A. Robinson MD | |
|---|---|
| Born | |
| 🎓 Alma mater | University of California, Los Angeles (MD), University of Virginia (Fellowships) |
| 💼 Occupation | Cardiologist, Medical researcher |
| 👔 Employer | Scripps Health |
Austin A. Robinson (born in the United States) is an American cardiologist and medical researcher specializing in advanced non-invasive cardiovascular imaging and outcomes related to anticoagulation management. He currently practices at Scripps Health in San Diego, California[1], and is known for his research challenging the use of Direct Oral Anticoagulants for left ventricular thrombi and for contributions to quantitative cardiac imaging methodology.[2]
Education and training
Robinson graduated with his Doctor of Medicine (MD) degree from the University of California, Los Angeles (UCLA) David Geffen School of Medicine in 2013.[3] He completed his Internal Medicine residency training at the] in 2016.
He pursued advanced sub-specialty training at the University of Virginia (UVA) School of Medicine, completing a Clinical Fellowship in Cardiovascular Disease in 2019, followed by a dedicated Cardiovascular Imaging Fellowship in 2020. This four-year research/clinical training period was supported, in part, by UVA's National Institute of Biomedical Imaging and Bioengineering (NIBIB)-funded Advanced Cardiovascular Imaging T32 grant, a mechanism designed to train physician-scientists.
During his time at Yale, Robinson co-authored a scholarly article on institutional surgical history, "Discovering a Surgical First: Russell M. Nelson and Tricuspid Valve Annuloplasty," published in the BYU Scholars Archive.[4]
Research and academic contributions
Robinson's academic work is focused on the comparative effectiveness of cardiovascular therapies and the standardization of advanced non-invasive diagnostic techniques.
Off-label anticoagulation for left ventricular thrombi
Robinson was the lead author of the study, "Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi," published in JAMA Cardiology in 2020.[5] The study, known as RED VELVT (Retrospective Evaluation of DOACs and Vascular Endpoints of Left Ventricular Thrombi), was a multicenter, retrospective, observational cohort analysis of 514 patients that examined outcomes following the off-label use of Direct Oral Anticoagulants (DOACs) for treating Left Ventricular (LV) Thrombi, which is not an FDA-approved indication for DOACs.[6]
The primary finding was that DOAC treatment was associated with a higher adjusted risk of stroke or systemic embolism (SSE) compared with the standard therapy, warfarin. Medscape Cardiology reported on the findings, noting that the adjusted risk for SSE was "more than doubled" in the DOAC group. Robinson stated that the research team was "shocked" by the counter-intuitive result. The research generated a notable clinical safety signal in the medical community.[7]
HCPLive reported on the study under the cautionary headline, "Off-Label DOAC Use Not Appropriate for LV Thrombi, Increases Stroke Risk," and concluded that clinicians "should be cautious in prescribing DOACs for off-label indications". Systematic reviews published in subsequent years frequently cite RED VELVT as the "largest retrospective study" investigating this use of DOACs[8][9] and acknowledge that it introduced "further uncertainty" into LVT management, thereby challenging the assumption of DOAC equivalence.[10] The study explicitly highlighted "the need for prospective randomized clinical trials to determine the most effective treatment strategies for LV thrombi".
Quantitative cardiovascular magnetic resonance
Robinson has also contributed to methodological advances in advanced cardiac imaging. He co-authored the 2019 technical review, "Myocardial T1 and ECV measurement: underlying concepts and technical considerations," published in JACC: Cardiovascular Imaging.[11] This paper focuses on the fundamental principles necessary for standardizing quantitative Cardiovascular Magnetic Resonance (CMR) techniques, specifically the measurement of Myocardial T1 and Extracellular Volume (ECV). The work is cited as a foundational reference by subsequent advanced imaging research, particularly for understanding the calculation of conventional ECV biomarkers.[12]
In addition, Robinson is listed as an author on systematic reviews and meta-analyses concerning the prognostic implications of Late Gadolinium Enhancement (LGE) on cardiac MRI across various cardiomyopathies.[13]
Intellectual property
During his research fellowship at UVA, Robinson secured funding from the Ivy Foundation for a project focused on developing a noninvasive, ultrasound-based therapy for degenerative mitral stenosis.[14]
This translational work led to the development of intellectual property. Robinson is listed as an Assignor (Inventor) on the United States patent US 12376824B2, which is formally assigned to the University of Virginia Patent Foundation and lists John A. Hossack as a co-inventor.[15]
Identity note
Austin A. Robinson, MD, the subject of this article, is distinct from Austin Robinson, PhD, an Associate Professor in the School of Kinesiology at Auburn University whose research focuses on neurovascular physiology, lifestyle factors, and racial disparities in vascular health[16][17], or Austin Robinson
References
- ↑ "Austin A. Robinson, MD: Cardiologist". Scripps Health. Retrieved September 28, 2025.
- ↑ "Austin A. Robinson: Citations". Google Scholar. Retrieved September 28, 2025.
- ↑ "Dr. Austin Robinson, MD". Scripps Health Profile. Retrieved September 28, 2025.
- ↑ Robinson, Austin A.; Eubanks, G.; Trankle, C. R. (2019). "Discovering a Surgical First: Russell M. Nelson and Tricuspid Valve Annuloplasty". BYU Scholars Archive. 54 (1): 3. Retrieved September 28, 2025.
- ↑ Robinson, AA; Trankle, CR; Eubanks, G; et al. (April 22, 2020). "Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi". JAMA Cardiology. 5 (6): 685–692. doi:10.1001/jamacardio.2020.0652. PMID 32275306 Check
|pmid=value (help). - ↑ Steve Stiles (April 28, 2020). "Cautions Raised Against Off-Label DOACs to Clear Left Ventricular Thrombi". Medscape Medical News. Retrieved September 28, 2025.
- ↑ "Off-Label DOAC Use Not Appropriate for LV Thrombi, Increases Stroke Risk". HCPLive. Retrieved September 28, 2025.
- ↑ Alhabeeb, W.; Tash, A.; Aljedai, A.; Morsy, A.; Khaliel, F.; Alhazmi, I.; Alsheef, M.; Arafah, M.; Alshammeri, O.; Alahmari, S. (2020). "Use of direct oral anticoagulants in the treatment of left ventricular thrombus: systematic review of current literature". Am J Therapeut. 27 (6): e584–e590. doi:10.1097/MJT.0000000000000937. PMC 11932698 Check
|pmc=value (help). PMID 40134412 Check|pmid=value (help). - ↑ "Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi". 2020. Retrieved September 28, 2025.
- ↑ May, J. E.; Moll, S. (2021). "Unexplained arterial thrombosis: approach to diagnosis and management". Hematology. ASH Publications. 2021 (1): 76–88. doi:10.1182/hematology.2021000235. PMC 8791102 Check
|pmc=value (help). PMID 34889390 Check|pmid=value (help). Retrieved September 28, 2025. - ↑ Robinson, AA; Chow, K; Salerno, M (November 2019). "Myocardial T1 and ECV measurement: underlying concepts and technical considerations". JACC: Cardiovascular Imaging. 12 (11 Part 2): 2332–2344. doi:10.1016/j.jcmg.2019.06.031. PMC 6895718 Check
|pmc=value (help). PMID 31607567. - ↑ Wu, W; et al. (December 10, 2021). "Synthetic extracellular volume fraction derived from the T1 time of the native blood pool: A narrative review". Circulation: Cardiovascular Imaging. 14 (12). doi:10.1161/CIRCIMAGING.121.013745. PMC 9015035 Check
|pmc=value (help). PMID 35360924 Check|pmid=value (help). Unknown parameter|article-number=ignored (help) - ↑ Helali, J; et al. (February 2025). "Late gadolinium enhancement on cardiac MRI: A systematic review and meta-analysis of prognosis across cardiomyopathies". International Journal of Cardiology. 419. doi:10.1016/j.ijcard.2024.132711. PMID 39515615 Check
|pmid=value (help). Unknown parameter|article-number=ignored (help) - ↑ "Austin Robinson MD, fellow on UVA's NIBIB-funded Advanced Cardiovascular Imaging T32 grant, was funded..." UVA Medicine Matters. July 16, 2018. Retrieved September 28, 2025.
- ↑ US patent 12376824B2, Robinson, Austin A.; Hossack, John A, "Systems and methods related to cardiac phases", issued March 26, 2024, assigned to University of Virginia Patent Foundation
- ↑ "Austin Robinson, PhD: Associate Professor, School of Kinesiology". Auburn University. Retrieved September 28, 2025.
- ↑ "Project Details: Mitochondria Dysfunction as a Contributor to Racial Disparities in Vascular Health and Hypertension". National Institutes of Health (NIH) RePORTER. Retrieved September 28, 2025.
External links
This article "Austin A. Robinson" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Austin A. Robinson. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
